Home Biologics

Keyword: Biologics

84 results found

Canada has one of the highest incidence rates of inflammatory bowel disease in the world. “We don’t know why, but Canada is one of the hotspots,” said Dr Mark Silverberg, gastroenterologist at Mount Sinai Hospital and the University of Toronto, during a webinar hosted by Benefits Canada and sponsored by Takeda Canada in November. IBD […]

The increasing use of high-cost medicines is the primary cost driver for all Canadian drug plans, according to a new report by the Patented Medicine Prices Review Board. It found drug costs for public plans rose by 5.3 per cent in 2019/20, with high-cost medicines accounting for 6.3 per cent of the increase. Among private […]

  • By: Staff
  • November 25, 2022 November 24, 2022
  • 09:00

The provision of employer-sponsored benefits has evolved significantly over the last 45 years, with the past decade ushering in the most consequential changes, fueled by technology, increased competition and demand. In the 80s and 90s, benefits plans were very siloed and one size fits all, says Chris Pryce, founder and president of Human Capital Benefits, […]

Total drug costs grew to $2 billion in 2021, rising steadily from $1.4 billion in 2017, according to Green Shield Canada’s annual drug trends report. The report, which is based on claims reported by Green Shield Canada, found the number of claimants also increased from 1.9 million to 2.1 million over the same period. While […]

  • By: Staff
  • September 23, 2022 September 22, 2022
  • 09:00

Severe asthma is a complex condition that impacts between 150,000 and 250,000 Canadians, according to Vanessa Foran, president and chief executive officer of Asthma Canada, during a webinar hosted last month by Benefits Canada and supported by AstraZeneca. It’s an acute condition where people have difficulty achieving control of their disease despite proper use of […]

While medications used for treating inflammatory disease accounted for just 0.7 per cent of claims across Telus Health’s Canadian block of business in 2021, they represent the largest percentage of eligible drug costs at 12.6 per cent, due to the prevalence of high-cost treatments in this drug class. By comparison, diabetes medications accounted for 12 […]

Copyright_Wavebreak Media Ltd_123RF

Changes to Quebec’s policy on the use of biosimilars in its public drug plan could result in savings for private benefits plans, says one expert. On April 13, 2022, the Régie de l’assurance maladie du Québec will delist certain biologic drugs from its formulary, requiring patients covered by the plan to switch to a biosimilar […]

It took an “intense, painful and scary” flare and emergency surgery at age 38 for Marie-Josée Lafleur (pictured right) to finally be diagnosed with inflammatory bowel disease, after being misdiagnosed for 15 years. IBD, which is typically diagnosed between ages 16 and 30, is caused by the body’s immune system attacking the gastrointestinal tract, creating […]

Copyright_Aleksandr Kalugin_123RF

In 2020, Canada Life Assurance Co. saw a decrease in the number of benefits plan members making a drug claim, though the costs of those claims were higher, according to Barb Martinez, the insurer’s national practice leader in drug solutions, speaking during a session at Benefits Canada‘s Face to Face in Drug Plan Management Forum […]

While one side highlights how plan sponsors can contribute to biosimilar sustainability, the other touts the benefits to patients and the health-care system. Durhane Wong-Rieger, president and chief executive officer, Institute for Optimizing Health Outcomes The Institute for Optimizing Health Outcomes recently published a scorecard rating the biosimilar policy frameworks of European countries across seven […]